Browsing by Author "Smith, I. E."
Now showing items 1-6 of 6
-
Article
Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
Constantinidou, Anastasia; Smith, I. E. (2011)Summary: Trastuzumab in combination with chemotherapy is now standard of care for patients with early HER2-positive cancers larger than 1 cm. Some patients however may not need or simply may not want chemotherapy with its ...
-
Article
Mitoxantrone (novantrone*) as single agent and in combination chemotherapy in the treatment of advanced breast cancer
Smith, I. E.; Stuart-Harris, R. C.; Pavlidis, Nicholas; Bozek, T. (1983)Nineteen out of 62 evaluable patients with advanced breast cancer achieved an objective tumour response to mitoxantrone (31%) given in a dose of 12-14 mg/m2 by i.v. infusion repeated at 3-weekly intervals. The response ...
-
Article
Mitoxantrone: An active new agent in the treatment of advanced breast cancer
Stuart-Harris, R. C.; Bozek, T.; Pavlidis, Nicholas; Smith, I. E. (1984)Sixty-five patients with advanced breast carcinoma were treated with mitoxantrone, an anthracenedione with structural similarities to adriamycin. The series included 26 patients who had received no prior chemotherapy. ...
-
Article
Re: Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis (multiple letters) [2]
Popat, S.; Smith, I. E.; Mauri, D.; Pavlidis, Nicholas; Ioannidis, J. P. A. (2005)
-
Article
Trastuzumab beyond Progression in HER2-Positive Advanced Breast Cancer: The Royal Marsden Experience
Waddell, T.; Kotsori, A.; Constantinidou, Anastasia; Yousaf, N.; Ashley, Sue; Parton, M.; Johnston, S. L.; Smith, I. E. (2010)
-
Article
Trastuzumab beyond progression in HER2-positive advanced breast cancer: The Royal Marsden experience
Waddell, T.; Kotsori, A.; Constantinidou, Anastasia; Yousaf, N.; Ashley, Sue; Parton, M.; Allen, M.; Starling, N.; Papadopoulos, P.; O'Brien, M.; Smith, I. E.; Johnston, S. L. (2011)BACKGROUND: Recent UK clinical guidance advises against continuing trastuzumab (T) beyond disease progression (PD) in the absence of brain metastases in patients with HER-2 positive (+ ve) advanced breast cancer. We have ...